Exploratory analysis of the ASCEND-1 study found that ceritinib was effective in ALK-rearranged NSCLC, including common EML4-ALK V3 and V1 variants, and novel ALK rearrangements, such as CRIM1-ALK and CLTC-ALK. Here, EML4 is linked to non-small cell lung carcinoma.